Geron Corp (GERN) 3.78 $GERN Most active Nasdaq-traded

New Post Public Reply Private Reply Replies (0) Message Board

Mar 5, 2015 at 10:04 PM

Geron Corp (GERN) 3.78 $GERN

Most active Nasdaq-traded stocks
AP - Thu Mar 05, 5:04PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 29.28 (+0.02), PCYC: 254.22 (+23.74), FB: 81.21 (+0.32), INTC: 33.73 (-0.39), OREX: 8.01 (-0.48), FOX: 34.03 (-0.04), GERN: 3.78 (+0.97), FOXA: 34.87 (-0.10), MSFT: 43.11 (+0.05), ZNGA: 2.41 (+0.02), AAPL: 126.41 (-2.13), CSCO: 29.30 (-0.03)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 11:45AM CST

CRMD: 7.76 (+1.60), EYES: 17.07 (+2.16), ECR: 6.57 (-0.62), CECE: 12.78 (-1.77), DRAM: 2.77 (-0.52), NVGN: 2.98 (-0.38), AMED: 28.35 (-1.08), VSLR: 11.35 (+2.82), MOMO: 11.09 (-1.46), GEF: 37.78 (-5.88), RNDY: 4.68 (+0.66), SMTC: 26.30 (-2.99), EVOK: 6.03 (+0.61), KYTH: 50.00 (+10.10), GERN: 3.78 (+0.97), LTRE: 1.73 (-0.18), ENRJ: 2.51 (+0.41), PEIX: 11.75 (+2.42), ALG: 59.19 (+9.29), CAPN: 7.37 (-1.38)

Geron gets boost from AbbVie-Pharmacyclics deal
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 11:15AM CST

JNJ: 102.52 (+0.87), PCYC: 254.22 (+23.74), GERN: 3.78 (+0.97), ABBV: 56.86 (-3.41)

Geron (GERN) Flagged As Strong On High Volume
at The Street - Thu Mar 05, 9:03AM CST
Trade-Ideas LLC identified Geron (GERN) as a strong on high relative volume candidate
GERN: 3.78 (+0.97)

Key Takeaways From Geron's Earnings Release
Kanak Kanti De - at Seeking Alpha - Wed Mar 04, 2:49PM CST

GERN: 3.78 (+0.97)

Geron's Q4 Loss Narrows Y/Y, Announces Restructuring Plan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 9:50AM CST
Geron Corporation (GERN) reported a fourth-quarter 2014 loss of 6 cents per share, a penny narrower than the year-ago loss of 7 cents. The Zacks Consensus Estimate was earnings of 17 cents.
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97), MRK: 57.98 (+0.10), BMY: 66.05 (+0.38)

Geron net loss improves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 8:13AM CST

GERN: 3.78 (+0.97)

Geron Is Proof That Biotech Bargains Still Exist
Stock Doctor - Seeking Alpha - Wed Mar 04, 8:13AM CST
With the biotechnology sector hitting new highs every day and small biotech stocks sporting billion dollar valuations with minimal drug data, there are not many bargains left on the market. A little over a month ago, I recommended the small cap...
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97)

Geron's (GERN) CEO Dr. John Scarlett on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 7:03PM CST

GERN: 3.78 (+0.97)

Geron reports 4Q loss
Automated Insights - Tue Mar 03, 4:54PM CST
MENLO PARK, Calif. (AP) _ Geron Corp. (GERN) on Tuesday reported a loss of $8.9 million in its fourth quarter.
GERN: 3.78 (+0.97)

Geron misses by $0.12
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 3:35PM CST

GERN: 3.78 (+0.97)

Geron (GERN) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Mar 03, 3:25PM CST

GERN: 3.78 (+0.97)

Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 4:35PM CST

AMBA: 64.39 (-3.10), BV: 6.26 (-0.15), AMRN: 1.67 (-0.02), AVAV: 25.80 (+0.15), BOBE: 47.76 (+1.40), TNET: 33.51 (-0.42), CECO: 6.00 (unch), VEEV: 24.73 (-0.99), REGI: 9.42 (-0.14), TIVO: 11.12 (-0.44), EGL: 34.91 (-0.56), ZLTQ: 31.76 (-0.29), LRE: 8.02 (-0.07), GERN: 3.78 (+0.97), ASNA: 13.24 (-0.14), CDXS: 3.99 (+0.09), SWHC: 14.40 (+0.06), ABM: 29.80 (+0.43)

What's in Store for Geron (GERN) this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 02, 12:00PM CST
Geron Corporation (GERN) is set to report fourth quarter 2014 results on Mar 3 after the market closes.
JNJ: 102.52 (+0.87), GERN: 3.78 (+0.97), AMRN: 1.67 (-0.02), PETX: 19.98 (+0.33)

Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 33.71 (-2.80), CASM: 1.37 (+0.03), AMRN: 1.67 (-0.02), XON: 49.50 (+1.39), OSIR: 16.94 (-0.86), CPIX: 6.75 (+0.12), AMED: 28.35 (-1.08), CTIC: 2.72 (+0.26), INSY: 57.61 (-0.46), ECYT: 6.25 (-0.48), CMRX: 40.79 (+0.05), KYTH: 50.00 (+10.10), TRIB: 18.52 (-0.08), GALE: 2.00 (+0.05), ARNA: 4.23 (-0.09), XLRN: 41.34 (+0.33), ACRX: 9.01 (-0.10), ENDP: 87.71 (+2.06), DPLO: 30.48 (-0.30), SLXP: 157.44 (+0.31), PPHM: 1.57 (+0.10), MYL: 56.69 (+1.09), CBPO: 81.80 (+2.09), RGEN: 25.78 (+0.67), HALO: 15.39 (-0.31), ALIM: 4.90 (-0.31), ACHN: 10.99 (-0.64), GERN: 3.78 (+0.97), DARA: 0.82 (-0.03), SCMP: 15.15 (+0.33), ICPT: 261.18 (-5.31), CDXS: 3.99 (+0.09), PCRX: 98.40 (+3.01), PBYI: 243.17 (+36.21), FOLD: 8.65 (+0.24)

Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 8:14AM CST

VRX: 203.95 (+0.80), OIBR: 2.17 (+0.02), CLDX: 29.78 (+0.48), HSBC: 43.59 (-0.17), ASTI: 1.45 (+0.11), AXN: 1.12 (+0.32), SPPI: 6.24 (-0.06), BIOC: 3.36 (-0.03), NBG: 1.51 (+0.08), RIGL: 3.30 (+0.22), BLDP: 2.35 (+0.08), MHR: 2.65 (-0.04), CSC: 69.86 (-0.20), PPO: 59.13 (+0.01), GERN: 3.78 (+0.97), ACI: 1.12 (-0.03), TSEM: 17.81 (+0.12), HOTR: 2.07 (-0.11), DGLY: 12.38 (-0.80), HLSS: 18.45 (+0.02), XOMA: 3.65 (-0.03)

Dr. Sergei Gryaznov: Geron Should Develop Imetelstat For ET/PV
Kanak Kanti De - at Seeking Alpha - Thu Feb 19, 7:37AM CST

GERN: 3.78 (+0.97)

Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 203.95 (+0.80), ACT: 295.70 (-0.44), MDT: 78.50 (+0.31), XON: 49.50 (+1.39), CTIC: 2.72 (+0.26), PFNX: 14.03 (+0.43), JNJ: 102.52 (+0.87), ANTM: 146.85 (+0.30), NVAX: 8.94 (+0.11), SHPG: 238.06 (-1.58), ABBV: 56.86 (-3.41), TBPH: 20.75 (-0.76), SNY: 48.36 (+0.02), ALQA: 5.36 (+0.02), REGN: 428.95 (+15.91), ONCY: 1.05 (+0.04), PFE: 34.47 (-0.17), SLXP: 157.44 (+0.31), EPRS: 11.47 (+0.07), AMGN: 159.60 (+0.41), NKTR: 13.30 (-0.09), ZTS: 46.46 (+0.23), GILD: 103.42 (+0.36), ACHN: 10.99 (-0.64), GERN: 3.78 (+0.97)

Some Color On Geron's Presentation At The BIO Conference
Kanak Kanti De - at Seeking Alpha - Tue Feb 10, 8:15PM CST

GERN: 3.78 (+0.97)

Momentum Indicators for Biotech Equities - PDL BioPharma, Geron, Celldex Therapeutics, XOMA Corp., and Juno Therapeutics
PR Newswire - Mon Feb 09, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Geron Corporation (NASDAQ: GERN), Celldex Therapeutics Inc. (NASDAQ: CLDX), XOMA Corporation (NASDAQ: XOMA), and Juno Therapeutics Inc. (NASDAQ: JUNO). Free research report on PDL BioPharma can be accessed at http://get.Investor-Edge.com/pdf/?c=PDL%20Bio...amp;s=PDLI. On Friday, February 06, 2015, the NASDAQ Composite ended at 4,744.40, down 0.43%, the Dow Jones Industrial Average declined 0.34%, to finish the day at 17,824.29, and the S&P 500 closed at 2,055.47, down 0.34%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 806.81, down 0.84%, while the index has advanced 4.07% in the last three months. Register for your complimentary reports at the links given below.
GERN: 3.78 (+0.97), CLDX: 29.78 (+0.48), JUNO: 52.03 (+2.03), XOMA: 3.65 (-0.03), PDLI: 7.10 (+0.14)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Power Knot MEA Wins THE BIZZ 2026 for Excellence

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Black Culture Icon: Plastic-Covered Couch Takes Stage

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Monster Energy Dominates Skateboard Podium at SLS Paris

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Monteverde Probes Four Key M&A Deals for Fairness

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Blokees Unveils 90+ New Wonders at Shanghai Fest

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Lawsuit Highlights Inaction in School Bus Tragedy

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...